Adrenal cortex disorder

Summary

Adrenal cortex disorder (MONDO:0002816) is a disease and 4 clinical trials. Top therapeutic interventions include cosyntropin. A subtype of adrenal gland disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 4

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	adrenal cortex disorder
Mondo ID	MONDO:0002816
MeSH	D000303
DOID	DOID:3952
SNOMED CT	129636003
UMLS	C0001614
MedGen	154
Anatomy (UBERON)	UBERON:0001235
Is cancer (heuristic)	no

Also known as: adrenal cortex disease · adrenal cortex disease or disorder · disease of adrenal cortex · disease or disorder of adrenal cortex · disorder of adrenal cortex

Disease family

This is a subtype of adrenal gland disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › endocrine system disorder › adrenal gland disorder › adrenal cortex disorder

Related subtypes (17): medulloadrenal hyperfunction, adrenal medullary hyperplasia, pituitary dwarfism, pseudoleprechaunism syndrome, Patterson type, apparent mineralocorticoid excess, autoimmune polyendocrine syndrome type 1, adrenomyodystrophy, corticosteroid-binding globulin deficiency, Congenital adrenal insufficiency with 46, XY sex reversal OR 46,XY disorder of sex development-adrenal insufficiency due to CYP11A1 deficiency, adrenogenital syndrome, hypoaldosteronism disease, primary pigmented nodular adrenocortical disease, adrenoleukodystrophy, adrenal gland neoplasm, ectopic ACTH secretion syndrome, endogenous Cushing syndrome, isolated micronodular adrenocortical disease

Subtypes (3): adrenocortical insufficiency, adrenal gland hyperfunction, adrenal cortex neoplasm

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01839812	PHASE1	COMPLETED	Adrenal Responsiveness During the Perioperative Period in Children Undergoing Congenital Cardiac Surgery
NCT06050057	Not specified	RECRUITING	Surgical Treatment of Adrenal Diseases- Laparoscopic vs. Robotic-assisted Adrenalectomy
NCT00385879	Not specified	UNKNOWN	The Effects of Case Management in a Medicaid Managed Care Plan
NCT02747355	Not specified	UNKNOWN	Expression of Different Proliferation Biomarkers in Adreno-cortical Tumors

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
COSYNTROPIN	4	1